PE20091373A1 - Sal monomaleato monohidrato de 7-metil-6-{2-[4-(2-metil-5-quinolinil)-1-piperazinil]etil}-4,5-dihidroimidazo[1,5-a]quinolin-3-carboxamida - Google Patents

Sal monomaleato monohidrato de 7-metil-6-{2-[4-(2-metil-5-quinolinil)-1-piperazinil]etil}-4,5-dihidroimidazo[1,5-a]quinolin-3-carboxamida

Info

Publication number
PE20091373A1
PE20091373A1 PE2009000045A PE2009000045A PE20091373A1 PE 20091373 A1 PE20091373 A1 PE 20091373A1 PE 2009000045 A PE2009000045 A PE 2009000045A PE 2009000045 A PE2009000045 A PE 2009000045A PE 20091373 A1 PE20091373 A1 PE 20091373A1
Authority
PE
Peru
Prior art keywords
methyl
salt
dihydroimidazo
quinolin
quinolinyl
Prior art date
Application number
PE2009000045A
Other languages
English (en)
Inventor
Clare Louise Anderton
Grahame Robert Woollam
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39165917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091373(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20091373A1 publication Critical patent/PE20091373A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

REFERIDA A UNA SAL MONOMALEATO MONOHIDRATO DE 7-METIL-6-{2-[4-(2-METIL-5-QUINOLINIL)-1-PIPERAZINIL]ETIL}-4,5-DIHIDROIMIDAZO[1,5-A]QUINOLIN-3-CARBOXAMIDA QUE TIENE UNA ESTRUCTURA CRISTALINA CON PICOS DE ABSORCION EN EL ESPECTRO DE INFRARROJO: 3573, 3460, 3298, 1662, 1579, 1494, 1442, 1088, 973, 866, 810 Y 748 cm-1. TAMBIEN ESTA REFERIDA A UN METODO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHA SAL TIENE ACTIVIDAD AGONISTA SOBRE EL RECEPTOR 5-HT1A Y ES UTIL EN EL TRATAMIENTO DE TRANSTORNOS PSICOTICOS, TRANSTORNOS DEL HUMOR, TRANSTRONOS DE ANSIEDAD, EN TRE OTROS
PE2009000045A 2008-01-17 2009-01-15 Sal monomaleato monohidrato de 7-metil-6-{2-[4-(2-metil-5-quinolinil)-1-piperazinil]etil}-4,5-dihidroimidazo[1,5-a]quinolin-3-carboxamida PE20091373A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0800840.1A GB0800840D0 (en) 2008-01-17 2008-01-17 Novel salt

Publications (1)

Publication Number Publication Date
PE20091373A1 true PE20091373A1 (es) 2009-10-14

Family

ID=39165917

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000045A PE20091373A1 (es) 2008-01-17 2009-01-15 Sal monomaleato monohidrato de 7-metil-6-{2-[4-(2-metil-5-quinolinil)-1-piperazinil]etil}-4,5-dihidroimidazo[1,5-a]quinolin-3-carboxamida

Country Status (10)

Country Link
US (1) US20100317672A1 (es)
EP (1) EP2238136A1 (es)
JP (1) JP2011509973A (es)
AR (1) AR070178A1 (es)
CL (1) CL2009000075A1 (es)
GB (1) GB0800840D0 (es)
PE (1) PE20091373A1 (es)
TW (1) TW200942540A (es)
UY (1) UY31601A1 (es)
WO (1) WO2009090202A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20060653A1 (es) 2004-08-31 2006-09-27 Glaxo Group Ltd Derivados triciclicos condensados como moduladores del receptor 5-ht1

Also Published As

Publication number Publication date
AR070178A1 (es) 2010-03-17
EP2238136A1 (en) 2010-10-13
TW200942540A (en) 2009-10-16
WO2009090202A1 (en) 2009-07-23
US20100317672A1 (en) 2010-12-16
UY31601A1 (es) 2009-08-31
CL2009000075A1 (es) 2011-02-11
GB0800840D0 (en) 2008-02-27
JP2011509973A (ja) 2011-03-31

Similar Documents

Publication Publication Date Title
ECSP10010390A (es) Compuestos
CL2008002042A1 (es) Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos.
EA201691172A1 (ru) Устройство для персонального использования в фототерапии
ATE544767T1 (de) Triazoloä4,5-düpyramidinderivate und deren verwendung als purinrezeptorantagonisten
BRPI0814529A2 (pt) Derivados de 2-3-dihidrobenzo[1,4]dioxin-2-ilmetil como antagonistas alfa2c para o uso no tratamento de doenças do sistema nervoso periférico e central.
CR20110318A (es) Compuestos, composición farmacéutica y métodos para utilizarse en el tratamiento de trastornos metabólicos
SV2006002245A (es) 2-anilinopirimidinas sustituidas como inhibidores de la quinasa del ciclo celular o del receptor de la tirosina quinasa, su preparacion y su uso como medicamentos ref. p-sv-78.797/msu
CL2007001972A1 (es) Ester isopropilico del acido 4-[6-(6-metanosulfonil-2-metilpiridin-3-ilamino)-5-metilpirimidin-4-iloxi]piperidin-1-carboxilico, moduladores del metabolismo; composicion farmaceutica; y su uso para tratar trastornos metabolicos.
HN2008001720A (es) Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina
CO6612267A2 (es) Nuevos derivados de 1,1 dióxido- 5 fenil- 2,3,4-5tetrahidro- 1,4-benzotiazepina y composiciones farmaceúticas que los comprenden
CL2013001723A1 (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina; metodos de preparacion; composicion farmaceutica; y el uso en el tratamiento de los trastornos mediados por la cinasa de linfoma anaplasico.
CL2007002272A1 (es) Compuestos derivados de n-metil-c-normorfinano; composicion farmaceutica; y uso para la reduccion de efectos secundarios del tratamiento de opioides tales como constipacion y nauseas, y para tratar trastornos mediados por la actividad de receptores o
CL2011002209A1 (es) Compuestos derivados de 2-mercaptoquinolin-3-carboxamida; medicamento que los comprende; y uso para tratar el dolor, epilepsia, incontinencia urinaria, ansiedad, dependencia manias, transtornos bipolares, migraña, enfermedades cognitivas, discinesia asociada a la distonia y/o incontinencia urinaria.
HUE047318T2 (hu) 1-benzil-3-hidroximetilindazol származékok és alkalmazásuk az MCP-1, CX3CR1 és P40 expresszióján alapuló betegségek kezelésében
SV2005002061A (es) Derivados de piridilo y su uso como antagonistas del receptor mglu5 ref. x-16538
IT1392903B1 (it) Composizione comprendente un'associazione di principi attivi per uso nel trattamento topico della calvizie
BRPI0511389A (pt) composição e seu uso
ECSP109890A (es) Particulas de un antagonista de crth2
ECSP11011294A (es) Compuestos de anillo fusionados y su uso
GEP20196969B (en) New therapeutical composition containing apomorphine as active ingredient
CL2013000736A1 (es) Uso de prodrogas ester de [3-(1-(1h-imidazol-4-il)etil)-2-metil-fenil]metanol para preparar un medicamento util en el tratamiento de enfermedades de la retina tales como degeneracion macular humeda y seca, y retinopatia diabetica; y uso de la composicion que comprende a dichos compuestos.
BRPI0910780A2 (pt) uso de antagonistas de opióides para o tratamento da retenção urinária
BRPI0506792A (pt) derivados de furosemida como moduladores de hm74 e seu uso no tratamento de inflamação
PE20130512A1 (es) Compuesto, composicion farmaceutica, uso de un compuesto y metodo para el tratamiento de los trastornos asociados a los receptores serotoninergicos 5-ht1a y 5-ht2a
BRPI0821114A2 (pt) Composto, uso de um composto e método para tratar qualquer mamífero afetado por câncer

Legal Events

Date Code Title Description
FD Application declared void or lapsed